glp-1 blue cross Prime Therapeutics' leading research shows only 1 in 12 remain on a drug for obesity at three years Anthem Blue Cross Blue Shield

The practical research interest is that amylin signaling reduces food intake through the hindbrain and area postrema a satiety route that is largely independent of incretin (GLP-1/GIP) signaling

Options are out-of-pocket payment for brand-name or compounded medication, or waiting for employer to change plan design during next open enrollment

The injection starts to work straight away

This is the first new medication approved since 2014 as an addition to diet and physical activity indicated for adults with obesity (initial BMI 30 kg/m2) or overweight (initial BMI 27 kg/m2) with at least one weight-related medical condition